CN113260363A - 格拉普兰特(grapiprant)单位剂型 - Google Patents

格拉普兰特(grapiprant)单位剂型 Download PDF

Info

Publication number
CN113260363A
CN113260363A CN201980072471.4A CN201980072471A CN113260363A CN 113260363 A CN113260363 A CN 113260363A CN 201980072471 A CN201980072471 A CN 201980072471A CN 113260363 A CN113260363 A CN 113260363A
Authority
CN
China
Prior art keywords
serum
dosage form
unit dosage
glatiramer
max
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980072471.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·曼弗雷迪
J·埃切迪
長久厚
奥村貴子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascat Ltd
Askat Inc
Ares Medical Ltd
Arrys Therapeutics Inc
Original Assignee
Ascat Ltd
Ares Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascat Ltd, Ares Medical Ltd filed Critical Ascat Ltd
Publication of CN113260363A publication Critical patent/CN113260363A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980072471.4A 2018-09-27 2019-09-27 格拉普兰特(grapiprant)单位剂型 Pending CN113260363A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862737285P 2018-09-27 2018-09-27
US62/737,285 2018-09-27
US201962834513P 2019-04-16 2019-04-16
US62/834,513 2019-04-16
PCT/US2019/053413 WO2020069288A1 (en) 2018-09-27 2019-09-27 Grapiprant unit dosage forms

Publications (1)

Publication Number Publication Date
CN113260363A true CN113260363A (zh) 2021-08-13

Family

ID=69953354

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980072471.4A Pending CN113260363A (zh) 2018-09-27 2019-09-27 格拉普兰特(grapiprant)单位剂型

Country Status (6)

Country Link
US (1) US20210353648A1 (cg-RX-API-DMAC7.html)
EP (1) EP3856177A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022500485A (cg-RX-API-DMAC7.html)
CN (1) CN113260363A (cg-RX-API-DMAC7.html)
CA (1) CA3113468A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020069288A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2021205367A1 (en) * 2020-04-08 2021-10-14 Askat Inc. Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia
CN115919756B (zh) * 2022-10-19 2024-08-23 梅州市珍宝金柚实业有限公司 一种金柚原浆口服液及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422779A1 (en) * 2009-04-22 2012-02-29 RaQualia Pharma Inc Selective ep4 receptor agonistic substance for treatment of cancer
US20150250773A1 (en) * 2014-03-06 2015-09-10 Aratana Therapeutics Inc. Compositions of grapiprant and methods for using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007011792D1 (de) * 2006-10-27 2011-02-17 Fmc Corp Gemeinsam aufbereitete mikrokristalline cellulose und zuckeralkohol als hilfsstoff für tablettenformulierungen
JP2014520865A (ja) * 2011-07-15 2014-08-25 ユーファーマ プロプライエタリー リミテッド 制酸剤、麻酔薬、ならびに二酸化ケイ素と二酸化チタンとを含んでなる無機マトリックスを含んでなる経口用組成物
CA2918277C (en) * 2013-07-16 2021-02-16 Cadila Pharmaceuticals Limited Indole-3-carbinol derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422779A1 (en) * 2009-04-22 2012-02-29 RaQualia Pharma Inc Selective ep4 receptor agonistic substance for treatment of cancer
US20120088723A1 (en) * 2009-04-22 2012-04-12 Raqualia Pharma Inc. Selective ep4 receptor agonistic substance for treatment of cancer
US20150250773A1 (en) * 2014-03-06 2015-09-10 Aratana Therapeutics Inc. Compositions of grapiprant and methods for using the same
CN105939713A (zh) * 2014-03-06 2016-09-14 阿莱塔纳治疗学股份有限公司 格拉匹纶组合物及其使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A NAGAHISA等: "Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs", 《J VET PHARMACOL THER》, vol. 40, no. 3, XP055698711, DOI: 10.1111/jvp.12349 *
L RAUSCH-DER等: "A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis", 《J VET INTERN MED》, vol. 30, no. 3 *

Also Published As

Publication number Publication date
EP3856177A1 (en) 2021-08-04
CA3113468A1 (en) 2020-04-02
EP3856177A4 (en) 2022-06-29
US20210353648A1 (en) 2021-11-18
JP2022500485A (ja) 2022-01-04
WO2020069288A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
CN116234931B (zh) 对nectin-4具有特异性的双环缀合物及其用途
US12577208B2 (en) TEAD inhibitors and uses thereof
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
US20220184222A1 (en) Bicycle toxin conjugates and uses thereof
JP2019142890A (ja) ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
US12295962B2 (en) Polymorphic compounds and uses thereof
JP2023553866A (ja) Tead阻害剤、及びその使用
JP2020528875A (ja) 血小板由来成長因子受容体アルファの遺伝的異常に関連する癌の治療のための、1−[4−ブロモ−5−[1−エチル−7−(メチルアミノ)−2−オキソ−1,2−ジヒドロ−1,6−ナフチリジン−3−イル]−2−フルオロフェニル]−3−フェニルウレアおよびアナログの使用
WO2023114984A1 (en) Tead inhibitors and uses thereof
US20210353648A1 (en) Grapiprant unit dosage forms
WO2023173053A1 (en) Mek inhibitors and uses thereof
CA3252253A1 (en) MEK INHIBITORS AND THEIR USES
US20230233546A1 (en) Methods of treating cancer
EA052011B1 (ru) Бициклические конъюгаты, специфические в отношении нектина-4, и варианты их применения
HK40017381A (en) Bicycle conjugate for treating cancer
HK40017381B (en) Bicycle conjugate for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210813